Elevance Health (ELV) Stock
Large US health insurer with Medicare and Medicaid plans. Here's the price, business snapshot, and what's worth knowing about Elevance Health in August 2026.
Elevance Health, Inc (ticker: ELV) is a large-cap US health-insurance conglomerate offering managed-care plans, Medicare and Medicaid services, and a growing set of digital and value-based care solutions. With a market capitalisation of about $77.73B, the company generates revenue from premiums, care-management services and partnerships with providers. Key drivers include membership growth—especially in Medicare Advantage and Medicaid—cost-management efforts and investments in data and digital tools. Investors should note exposure to medical-cost trends, regulatory change and reimbursement pressures, which can affect margins and earnings volatility. The business has scale and diversification across commercial and government programmes, but returns are not guaranteed and share prices can fall as well as rise. This summary is for general educational purposes only and is not personalised investment advice; investors should consider their own risk tolerance, diversification needs and consult a financial adviser where appropriate.
Why It’s Moving
ELV stays in focus as strong earnings and steady analyst support keep the bull case alive
- Analysts remain constructive after Elevance Health’s second-quarter results topped expectations, reinforcing the view that earnings momentum is still holding up even as bottom-line growth eased year over year.
- The stock has continued to trade near the $400 level, suggesting investors are leaning on the company’s recent profitability and guidance strength rather than focusing only on short-term share-price swings.
- Fresh note activity has kept sentiment positive, with new investment positions and broad buy ratings signaling that institutions still see room for the healthcare insurer’s fundamentals to re-rate.
ELV stays in focus as strong earnings and steady analyst support keep the bull case alive
- Analysts remain constructive after Elevance Health’s second-quarter results topped expectations, reinforcing the view that earnings momentum is still holding up even as bottom-line growth eased year over year.
- The stock has continued to trade near the $400 level, suggesting investors are leaning on the company’s recent profitability and guidance strength rather than focusing only on short-term share-price swings.
- Fresh note activity has kept sentiment positive, with new investment positions and broad buy ratings signaling that institutions still see room for the healthcare insurer’s fundamentals to re-rate.
next-earnings-question
The next expected earnings date for ELV is October 21, 2026, based on its historical reporting pattern. That release would cover Q3 2026 results. The company has not formally confirmed the date yet, so it remains an estimated timetable.
Why You’ll Want to Watch This Stock
Membership Growth Drivers
Medicare Advantage and Medicaid enrolment trends can support revenue expansion, though membership quality and medical costs influence outcomes.
US Market Exposure
Elevance is focused on the US health ecosystem and benefits from demographic ageing, but it remains sensitive to domestic policy and regulation.
Digital Innovation Push
Investments in data and care-management tech aim to reduce costs and improve outcomes, though execution and competition present ongoing risks.
